# US 2012/0255043 A1 · Microrna as a cancer progression predictor and its use for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0255043 A1
- Document ID: US20120255043A1
- Status: Published application
- Kind: A1
- Application number: 13/074,719
- Filed: 2011-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Taipei Veterans General Hospital
- Inventors: Shih-Hwa Chiou; Guang-Yuh Chiou
- Web page: https://patentgrep.com/patent/US20120255043A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/315: Phosphorothioates
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/31: Combination therapy
- C12N 2330/10: naturally occurring
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.

## Claims

### Claim 1

A method for suppressing the expression of a target gene in a cell, comprising introducing miR142-3p into the cell, wherein the target gene encoding CD133, Sox2, or AC9.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the miR142-3p directly connects to 3′ side untranslated regions (3′ UTR) of the mRNA of the target gene.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cell is a recurrent glioblastoma multiforme (GBM) cell.

### Claim 4

A method for diagnosing or predicting whether a subject has, or is at risk for developing recurrent glioblastoma multiforme after treatment, comprising:
(a) measuring the level of miR142-3p in a control sample from the subject with primary GBM;
(b) measuring the level of miR142-3p in a test sample from the same subject after treatment; and
(c) comparing the level of miR142-3p in the test sample of step (b) to the level of miR142-3p in the control sample of step (a),
wherein the level of miR142-3p in the test sample of step (b) lower than the level of miR142-3p in the control sample of step (a) by indicates that the subject has, or is at risk for developing recurrent glioblastoma multiforme after treatment.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the subject has been subjected to surgical treatment, chemical treatment, radio therapy, or a combination thereof

### Claim 6 (depends on 4)

The method according to claim 4, wherein a decrease in the level of miR142-3p is indicative of adverse prognosis.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the subject is a patient having grade I, II, III, or IV glioma.

### Claim 8

A method for treating glioblastoma multiforme in a subject, comprising administering a therapeutically effective amount of miR142-3p to the subject in need thereof.

### Claim 9 (depends on 8)

The method according to claim 8, wherein miR142-3p is administered into a tumor locus by a stereotaxic apparatus.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the glioblastoma multiforme is recurrent glioblastoma multiforme.

### Claim 11 (depends on 8)

The method according to claim 8, wherein miR142-3p is encoded by a nucleic acid.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the nucleic acid is located on a vector.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the vector is selected from the group consisting of a plasmid, cosmid, phagemid, or a virus.

### Claim 14 (depends on 8)

The method according to claim 8, wherein miR142-3p is a modified microRNA with LNA- and phosphorothioate-modified backbone.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the modified microRNA is encapsulated by liposome.

### Claim 16

A method for producing a glioblastoma multiforme animal model, comprising:
(a) preparing a primary glioma cell;
(b) introducing a miR142-3p antisense oligonucleotide into the primary glioma cell to obtain a miR142-3p depleted cells;
(c) transplanting the miR142-3p depleted cells to an animal to obtain the animal suffering from glioblastoma multiforme.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the animal is mouse.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the number of miR142-3p depleted cells transplanted into the animal is 1˜1000 cells.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the number of miR142-3p depleted cells transplanted into the animal is 50 cells.

### Claim 20

A method for increasing the sensitivity of a glioblastoma multiforme cell to radiotherapy comprising administering a therapeutically effective amount of miR142-3p to the glioblastoma multiforme cell.

### Claim 21 (depends on 20)

The method according to claim 20, wherein miR142-3p is administered into a tumor locus by a stereotaxic apparatus.

### Claim 22 (depends on 20)

The method according to claim 20, wherein miR142-3p is encoded by a nucleic acid.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the nucleic acid is located on a vector.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the vector is selected from the group consisting of a plasmid, cosmid, phagemid, or a virus.

### Claim 25 (depends on 20)

The method according to claim 20, wherein miR142-3p is a modified microRNA with LNA- and phosphorothioate-modified backbone.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the modified microRNA is encapsulated by liposome.
